Zhengye Biotechnology Holding (ZYBT) Total Non-Current Liabilities (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Total Non-Current Liabilities for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 95.82% year-over-year to $1.3 million in Q4 2025; TTM through Dec 2025 was $1.3 million, a 95.82% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 101.82% from the prior year.
• Total Non-Current Liabilities was $1.3 million for Q4 2025 at Zhengye Biotechnology Holding, up from $656000.0 in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.4 million in Q4 2023 and troughed at $656000.0 in Q2 2025.
• A 3-year average of $1.0 million and a median of $988393.9 in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities tumbled 53.66% in 2024 and jumped 95.82% in 2025, its largest moves.
• Over 3 years, Total Non-Current Liabilities stood at $1.4 million in 2023, then plunged by 53.66% to $668235.5 in 2024, then jumped by 95.82% to $1.3 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $1.3 million (Q4 2025), $656000.0 (Q2 2025), and $668235.5 (Q4 2024), per Business Quant data.